Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 14Nivolumab 10atezolizumab 5durvalumab 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4avelumab 3Specimen Handling 3Radiosurgery 3Magnetic Resonance Spectroscopy 3temsirolimus 2poly ICLC 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2budigalimab 2aldesleukin 2abiraterone 2Radiotherapy 2Interleukin-2 2Gemcitabine 2venetoclax 1utomilumab 1trastuzumab deruxtecan 1tislelizumab 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × SGN-LIV1A × Dermatologic × Clear all
NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 2 Terminated
205 enrolled 54 charts
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡